First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70. (Q38941987)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26576779%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

title

First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70 (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26576779%20AND%20SRC:MED&resulttype=core&format=json

multicenter clinical trial

29 February 2020

main subject

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26576779%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

author name string

Taofeek Kunle Owonikoko

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26576779%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Arif Hussain

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26576779%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Walter Michael Stadler

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26576779%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Harriet Kluger

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26576779%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Ana M Molina

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26576779%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Parul Gulati

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26576779%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Aadhar Shah

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26576779%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Christoph Matthias Ahlers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26576779%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Pina M Cardarelli

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26576779%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Lewis J Cohen

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26576779%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

publication date

14 November 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26576779%20AND%20SRC:MED&resulttype=core&format=json

Cancer Chemotherapy and Pharmacology

29 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26576779%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26576779%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26576779%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

page(s)

155-162

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26576779%20AND%20SRC:MED&resulttype=core&format=json

Antibody conjugate therapeutics: challenges and potential

29 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2909-2

Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2909-2

Novel detection of DNA-alkylated adducts of antibody-drug conjugates with potentially unique preclinical and biomarker applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2909-2

CD27 and CD70 in T cell and B cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2909-2

Expression of CD27-CD70 on early B cell progenitors in the bone marrow: implication for diagnosis and therapy of childhood ALL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2909-2

CD70 (TNFSF7) is expressed at high prevalence in renal cell carcinomas and is rapidly internalised on antibody binding.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2909-2

CD70: a new tumor specific biomarker for renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2909-2

Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2909-2

CD70 as a therapeutic target in human malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2909-2

Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2909-2

Potent anticarcinoma activity of the humanized anti-CD70 antibody h1F6 conjugated to the tubulin inhibitor auristatin via an uncleavable linker

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2909-2

Molecular basis for sequence selective DNA alkylation by (+)- and ent-(-)-CC-1065 and related agents: alkylation site models that accommodate the offset AT-rich adenine N3 alkylation selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2909-2

Anticellular and antitumor activity of duocarmycins, novel antitumor antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2909-2

Phase II trial of KW2189 in patients with advanced malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2909-2

A phase II pilot study of KW-2189 in patients with advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2909-2

A phase I study of bizelesin, a highly potent and selective DNA-interactive agent, in patients with advanced solid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2909-2

Trastuzumab emtansine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2909-2

Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2909-2

Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2909-2

The next generation of antibody drug conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2909-2

Exposure-response relationship of T-DM1: insight into dose optimization for patients with HER2-positive metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2909-2

Bioanalysis of antibody-drug conjugates: American Association of Pharmaceutical Scientists Antibody-Drug Conjugate Working Group position paper

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2909-2